Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypogonadism 4 Eunuchism 2 Testicular Neoplasms 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 1 1 Klinefelter Syndrome 1 Infertility 1 Fatigue Syndrome, Chronic 1 Carcinoma, Renal Cell 1

Interventions

Nivolumab 143 pembrolizumab 129 Sunitinib 127 Bevacizumab 71 Everolimus 70 Sorafenib 68 cabozantinib 64 Ipilimumab 61 pazopanib 58 Axitinib 57 aldesleukin 51 Magnetic Resonance Spectroscopy 43 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 36 Radiosurgery 36 Specimen Handling 33 Interferon-alpha 32 atezolizumab 29 belzutifan 24 temsirolimus 23 Gemcitabine 23 fludarabine phosphate 22 Radiotherapy 18 Interferon alpha-2 18 Biopsy 18 fludarabine 17 durvalumab 17 avelumab 17 Paclitaxel 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × testosterone undecanoate × Clear all

NCT03379012 2019-10-22

FARETES

Kidney Cancer Research Bureau

Phase 2 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡